EMA recommended 114 new medicines and 46 new active substances for approval in 2024
The Agency recommended, among others, the first medicine to treat early Alzheimer’s disease, the first needle-free and smaller form of adrenaline to treat allergic reactions, the first treatment for tumours associated with von Hippel-Lindau disease, and two new antibiotic medicines for the treatment of certain severe infections.